Filtrer vos résultats
- 3
- 1
- 4
- 4
- 2
- 1
- 1
- 4
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 4
- 4
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life ExperienceBlood, 2022, 140 (Supplement 1), pp.12335-12338. ⟨10.1182/blood-2022-163478⟩
Article dans une revue
hal-04031847v1
|
||
|
Prognostic significance of concurrent gene mutations i n intensively treated patients with IDH-mutated AML: an ALFA studyBlood, 2021, 137 (20), pp.2827-2837. ⟨10.1182/blood.2020010165⟩
Article dans une revue
hal-03604929v1
|
||
|
Therapy Related Myeloid Neoplasms Following PARP Inhibitors: Real-Life Experience.Clinical Cancer Research, 2022, pp.CCR-22-1622. ⟨10.1158/1078-0432.CCR-22-1622⟩
Article dans une revue
hal-03814212v1
|
||
|
Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AMLBlood, 2019, 134 (1), ⟨10.1182/blood-2019-127082⟩
Article dans une revue
hal-03605008v1
|